TG Therapeutics
TGTX
52.95
+0.76
+1.46%
TG Therapeutics
US · TGTX
#1638 by market cap
Listed 1970
52.95
+0.76
+1.46%
Live - 5344 symbols - heartbeat 9s ago
· 2026-10-08 07:30
Pre-market
52.94
-0.02%
After-hours
53.18
+0.43%
- Market cap
- 8.11B
- P/E (TTM)i
- 19.32
- P/Bi
- 13.42
- EPSi
- 2.77
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on TGTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 11.79, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +87.32% YoY
Margins
- Gross margin
- 83.66%
- Operating margin
- 20.01%
- Net margin
- 72.56%
Key ratios & quality
- Enterprise valuei
- 8.21B
- Altman Z-Scorei
- 11.79
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 152.00K | 152.00K | 152.00K | 6.69M | 2.79M | 233.66M | 329.00M | 616.29M |
| Gross profit | -- | 152.00K | 152.00K | 5.90M | 2.52M | 219.53M | 290.52M | 515.57M |
| Selling & admin expenses | 15.16M | 15.03M | 107.85M | 128.09M | 95.48M | 122.71M | 154.30M | 232.03M |
| Research & development | 159.39M | 154.18M | 165.90M | 222.58M | 125.35M | 76.19M | 94.29M | 160.22M |
| Operating profit | -174.40M | -169.06M | -273.59M | -344.77M | -218.32M | 20.63M | 41.93M | 123.32M |
| Pretax profit | -173.48M | -172.87M | -279.38M | -348.10M | -223.81M | 13.06M | 25.59M | 107.39M |
| Tax | -- | -- | -- | 0 | 0 | 390.00K | 2.21M | -339.79M |
| Net profit | -173.48M | -172.87M | -279.38M | -348.10M | -223.81M | 12.67M | 23.38M | 447.18M |
| Basic EPS | -2 | -2 | -2 | -3 | -2 | 0 | 0 | 3 |
| Diluted EPS | -2.30 | -1.96 | -2.42 | -2.63 | -1.65 | 0.09 | 0.15 | 2.77 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 120.86M | 141.15M | 161.71M | 192.57M | 204.92M | 240.34M |
| Gross profit | 105.32M | 122.21M | 133.62M | 154.43M | 171.41M | 199.14M |
| Selling & admin expenses | 50.33M | 55.59M | 63.37M | 62.75M | 88.22M | 82.13M |
| Research & development | 46.36M | 31.78M | 40.88M | 41.19M | 48.40M | 95.34M |
| Operating profit | 8.62M | 34.84M | 29.37M | 50.49M | 34.80M | 21.67M |
| Pretax profit | 5.47M | 30.92M | 25.91M | 45.09M | 20.36M | 10.23M |
| Tax | 408.00K | 2.73M | -364.99M | 22.06M | 586.00K | 2.45M |
| Net profit | 5.06M | 28.19M | 390.90M | 23.04M | 19.78M | 7.78M |
| Basic EPS | 0 | 0 | 3 | 0 | 0 | 0 |
| Diluted EPS | 0.03 | 0.17 | 2.43 | 0.14 | 0.12 | 0.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 79.03M | 149.15M | 611.74M | 330.97M | 168.27M | 317.94M | 566.36M | 630.76M |
| Cash & ST investments | 68.90M | 140.44M | 605.43M | 314.76M | 161.68M | 217.51M | 311.00M | 141.97M |
| Inventory | -- | -- | -- | -- | 0 | 39.82M | 110.46M | 125.59M |
| Total assets | 83.62M | 163.01M | 625.64M | 379.63M | 193.57M | 329.59M | 577.69M | 1.06B |
| Total current liabilities | 38.85M | 84.45M | 87.55M | 65.38M | 53.20M | 53.72M | 90.68M | 153.76M |
| Short-term debt | -- | 1.62M | 23.85M | 2.41M | 1.58M | 1.45M | 1.16M | 1.04M |
| Long-term debt | -- | 28.97M | 7.72M | 66.79M | 71.14M | 100.12M | 244.43M | 245.65M |
| Total liabilities | 59,580,000.00 | 124,399,000.00 | 106,292,000.00 | 142,476,000.00 | 134,985,000.00 | 169,085,000.00 | 355,326,000.00 | 415,233,000.00 |
| Total equity | 24.04M | 38.62M | 519.35M | 237.15M | 58.59M | 160.50M | 222.36M | 648.02M |
| Retained earnings | -528.35M | -701.22M | -980.60M | -1.33B | -1.53B | -1.55B | -1.53B | -1.08B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 644.51M | 663.96M | 599.77M | 630.76M | 1.09B | 1.15B |
| Cash & ST investments | 276.24M | 251.87M | 131.58M | 141.97M | 514.43M | 552.25M |
| Inventory | 157.76M | 155.20M | 146.95M | 125.59M | 129.03M | 147.97M |
| Total assets | 656.69M | 702.61M | 1.03B | 1.06B | 1.53B | 1.64B |
| Total current liabilities | 160.21M | 171.89M | 156.81M | 153.76M | 187.11M | 268.49M |
| Short-term debt | 1.12M | 1.09M | 1.07M | 1.04M | 1.82M | 1.91M |
| Long-term debt | 244.73M | 245.04M | 245.34M | 245.65M | 745.14M | 745.39M |
| Total liabilities | 419,400,000.00 | 426,181,000.00 | 417,806,000.00 | 415,233,000.00 | 945,706,000.00 | 1,035,546,000.00 |
| Total equity | 237.29M | 276.43M | 607.22M | 648.02M | 583.13M | 604.08M |
| Retained earnings | -1.52B | -1.50B | -1.11B | -1.08B | -1.06B | -1.05B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -128.93M | -132.81M | -214.51M | -295.63M | -176.17M | -31.41M | -40.52M | -24.77M |
| Depreciation & amortization | 223.00K | 282.00K | 374.00K | 494.00K | 515.00K | 423.00K | 280.00K | 244.00K |
| Free cash flow | -129.02M | -132.94M | -214.86M | -296.04M | -176.18M | -31.41M | -40.56M | -24.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 113.64M | 175.02M | 679.68M | 2.22M | 0 | 46.30M | -8.76M | -91.24M |
| Ending cash balance | 43.20M | 113.89M | 554.70M | 300.15M | 103.58M | 94.22M | 181.19M | 80.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -28.72M | 7.44M | -23.15M | 19.66M | -17.89M | 39.26M |
| Depreciation & amortization | 56.00K | 59.00K | 62.00K | 67.00K | 80.00K | 96.00K |
| Free cash flow | -28.74M | 7.39M | -23.23M | 19.59M | -17.95M | 38.97M |
| Dividends paid | 0 | 0 | -- | -- | 0 | 0 |
| Stock buybacks / issuance | -6.12M | -6.88M | -78.24M | 0 | -99.99M | 0 |
| Ending cash balance | 133.44M | 130.44M | 75.41M | 80.49M | 443.56M | 483.94M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -381.16 | -551.85 | -100.14 | -92.03 | -134.13 | 11.57 | 12.21 | 102.75 |
| ROA %i | -191.70 | -140.19 | -70.85 | -69.26 | -69.20 | 4.84 | 5.15 | 54.50 |
| ROIC %i | -382.22 | -234.86 | -85.23 | -78.05 | -82.19 | 12.06 | 12.13 | 67.98 |
| 5-year avg ROE %i | -177.51 | -269.31 | -275.48 | -271.11 | -255.31 | -176.76 | -63.95 | -23.37 |
| EBIT margin %i | -114,736.84 | -110,252.63 | -179,639.47 | -5,119.79 | -6,755.62 | 10.99 | 15.08 | 21.76 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.03 | 1.77 | 6.99 | 5.06 | 3.16 | 5.92 | 6.25 | 4.10 |
| Quick ratioi | 1.77 | 1.66 | 6.91 | 4.84 | 3.04 | 5.00 | 4.85 | 2.91 |
| Debt / assetsi | 0.00 | 25.03 | 6.71 | 20.82 | 42.91 | 33.62 | 43.92 | 23.86 |
| LT debt / equityi | -- | 101.48 | 3.49 | 32.31 | 139.07 | 68.13 | 113.58 | 38.99 |
| Interest coveragei | -- | -31.70 | -43.14 | -60.74 | -18.46 | 2.04 | 2.07 | 5.02 |
| Revenue CAGR (3Y) %i | -0.08 | 0.00 | 0.00 | 253.05 | 163.63 | 1,054.11 | 266.39 | 504.86 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.70 | 26.63 | 111.96 | 102.75 | 112.60 | 100.28 |
| ROA %i | 7.60 | 10.95 | 55.55 | 54.50 | 42.27 | 37.70 |
| ROIC %i | 17.27 | 21.71 | 71.77 | 67.98 | 52.36 | 49.13 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.18 | 21.44 | 21.62 | 21.76 | 21.41 | 17.40 |
| FCF / sales %i | -- | -- | -- | -- | -- | 2.17 |
| Current ratioi | 4.02 | 3.86 | 3.82 | 4.10 | 5.81 | 4.27 |
| Quick ratioi | 2.91 | 2.81 | 2.53 | 2.91 | 4.84 | 3.55 |
| Debt / assetsi | 38.63 | 36.11 | 24.75 | 23.86 | 49.29 | 46.01 |
| LT debt / equityi | 106.45 | 91.39 | 41.61 | 38.99 | 128.91 | 124.57 |
| Interest coveragei | 2.46 | 3.12 | 4.22 | 5.02 | 5.42 | 3.71 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
B-cell mediated disease therapy100.00%
Quote time 2026-10-08 07:30:45 · For reference only, not investment advice and not tailored to your situation.